Takeda licensed exclusive rights to ImmunoGen Inc.'s (Nasdaq: IMGN) ADC
technology to develop and commercialize targeted anticancer
therapeutics. The stock price climbed $1.26 to $8.70.
Takeda licenses ImmunoGen's ADC technology
March 23, 2015 at 14:24 PM EDT